Elevated Level of Circulating but Not Urine S100A8/A9 Identifies Poor COVID-19 Outcomes.
COVID-19
S100A8/A9
biomarker
calprotectin
prognosis
Journal
ACS infectious diseases
ISSN: 2373-8227
Titre abrégé: ACS Infect Dis
Pays: United States
ID NLM: 101654580
Informations de publication
Date de publication:
13 10 2023
13 10 2023
Historique:
medline:
23
10
2023
pubmed:
3
10
2023
entrez:
3
10
2023
Statut:
ppublish
Résumé
The alarmin calprotectin (S100A8/A9) is thought to drive a cytokine storm, a hallmark of severe COVID-19. Recent studies report circulating S100A8/A9 levels can distinguish COVID-19 severity but have only been conducted in non-U.S. cohorts and mainly focus on serum S100A8/A9 levels. Thus, we quantified S100A8/A9 in serum and urine samples from a hospital cohort in St. Louis, Missouri, to expand the understanding of S100A8/A9 as a prognostic biomarker for COVID-19. Elevated S100A8/A9 serum levels were observed in ICU patients (
Identifiants
pubmed: 37787461
doi: 10.1021/acsinfecdis.3c00249
pmc: PMC10580308
doi:
Substances chimiques
Calgranulin B
0
Calgranulin A
0
Leukocyte L1 Antigen Complex
0
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1815-1820Subventions
Organisme : NIAID NIH HHS
ID : R01 AI111914
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007317
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002345
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA091842
Pays : United States
Références
J Infect. 2021 Apr;82(4):84-123
pubmed: 33217473
Arthritis Res Ther. 2017 Oct 24;19(1):242
pubmed: 29065913
Exp Biol Med (Maywood). 2017 Apr;242(8):859-873
pubmed: 27895095
Genes Genomics. 2023 Mar;45(3):337-346
pubmed: 36107397
PLoS One. 2013 Jul 18;8(7):e68694
pubmed: 23874727
Cell Host Microbe. 2021 Feb 10;29(2):222-235.e4
pubmed: 33388094
Am J Respir Crit Care Med. 2013 Nov 1;188(9):1137-46
pubmed: 24047412
J Leukoc Biol. 2021 Jan;109(1):67-72
pubmed: 32869342
J Clin Med. 2021 Feb 15;10(4):
pubmed: 33672040
EBioMedicine. 2022 Jun;80:104077
pubmed: 35644124
Cell. 2020 Sep 17;182(6):1401-1418.e18
pubmed: 32810439
Front Immunol. 2018 Jun 11;9:1298
pubmed: 29942307
J Clin Invest. 2012 Aug;122(8):2711-9
pubmed: 22850880
Nat Immunol. 2017 Jun;18(6):622-632
pubmed: 28459433
J Infect. 2021 Feb;82(2):e40-e42
pubmed: 32795482
Nature. 2002 Dec 19-26;420(6917):846-52
pubmed: 12490957
J Clin Lab Anal. 2023 Jan;37(1):e24809
pubmed: 36525302
Cell Mol Immunol. 2020 Sep;17(9):992-994
pubmed: 32620787
Blood. 2019 Jul 11;134(2):134-146
pubmed: 31076441
J Clin Invest. 2020 Jun 1;130(6):3098-3112
pubmed: 32134742
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
Lupus Sci Med. 2022 Mar;9(1):
pubmed: 35246487
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Nat Med. 2007 Sep;13(9):1042-9
pubmed: 17767165
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Rev Immunol. 2010 Dec;10(12):826-37
pubmed: 21088683
Inflamm Res. 2022 Mar;71(3):369-376
pubmed: 35217896
RMD Open. 2020 Jul;6(2):
pubmed: 32723832
Clin Chem Lab Med. 2022 Dec 06;61(3):494-502
pubmed: 36473060
Clin Nephrol. 2023 Apr;99(4):161-171
pubmed: 36683554
Cell Rep. 2014 Dec 24;9(6):2112-23
pubmed: 25497086
Future Med Chem. 2017 Feb;9(2):169-178
pubmed: 28128003
J Infect. 2022 Mar;84(3):e31-e33
pubmed: 35074506
Ir J Med Sci. 2022 Feb;191(1):59-64
pubmed: 33641087
Healthcare (Basel). 2021 Jul 29;9(8):
pubmed: 34442092
Eur J Endocrinol. 2012 Oct;167(4):569-78
pubmed: 22822112
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1372-1379
pubmed: 32242738
Int J Mol Med. 2017 Jul;40(1):31-38
pubmed: 28498464